Several studies elucidated the distinct gene expression profiles between the AML-NK patients and refinement based on genomic aberrations such as the mutational status of prognostic genes (FLT3-ITD, CEBPA and NPM1) [17,18,19,20]. The gene discussed is FLT3; the disease is acute myeloid leukemia.